Direct oral anticoagulant versus antiplatelet therapy following transcatheter aortic valve replacement in patients without prior or concurrent indication for anticoagulation: A meta-analysis of randomized studies.
Matheus Jose Barbosa MoreiraNatália Araújo do Amaral PeixotoOfonime Chantal Udoma-UdofaSílvia L S de AraújoShirley Katherine Tinajero EnriquezPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2022)
In this meta-analysis of randomized studies comparing DOACs to antiplatelet therapy after TAVR in patients without a concomitant indication for anticoagulation, DOACs were associated with a lower incidence of valve thrombosis and a higher rate of all-cause mortality, driven by an increase in noncardiac causes of death.
Keyphrases
- antiplatelet therapy
- transcatheter aortic valve replacement
- ejection fraction
- end stage renal disease
- aortic stenosis
- acute coronary syndrome
- percutaneous coronary intervention
- systematic review
- chronic kidney disease
- newly diagnosed
- venous thromboembolism
- prognostic factors
- double blind
- open label
- pulmonary embolism
- randomized controlled trial
- squamous cell carcinoma
- placebo controlled
- phase iii
- mitral valve
- direct oral anticoagulants
- patient reported outcomes
- case control
- locally advanced
- rectal cancer